Díaz-Santiago, ElenaRodríguez-Caso, LuisCárdenas, CasimiroSerrano, José JQuesada, Ana RMedina, Miguel Ángel2023-01-252023-01-252016-05-19http://hdl.handle.net/10668/10106We studied the modulatory effects of homocysteine pre-treatment on the disulfide reduction capacity of tumor and endothelial cells. Human MDA-MB-231 breast carcinoma and bovine aorta endothelial cells were pre-treated for 1-24 hours with 0.5-5 mM homocysteine or homocysteine thiolactone. After washing to eliminate any rest of homocysteine or homocysteine thiolactone, cell redox capacity was determined by using a method for measuring disulfide reduction. Homocysteine pre-treatments for 1-4 hours at a concentration of 0.5-5 mM increase the disulfide reduction capacity of both tumor and endothelial cells. This effect cannot be fully mimicked by either cysteine or homocysteine thiolactone pre-treatments of tumor cells. Taken together, our data suggest that homocysteine can behave as an anti-oxidant agent by increasing the anti-oxidant capacity of tumor and endothelial cells.enBovine aortic endothelial cellsCysteineHomocysteineHomocysteine thiolactoneMDA-MB231 breast cancer cellRedoxAntioxidantsCell Line, TumorEndothelial CellsHomocysteineHumansNeoplasmsOxidation-Reductionresearch article27198616open access10.1080/13510002.2016.11833481743-2928PMC6837415https://www.tandfonline.com/doi/pdf/10.1080/13510002.2016.1183348?needAccess=truehttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6837415/pdf